Literature DB >> 20538469

1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.

Bader A Salameh1, Ian Cumpstey, Anders Sundin, Hakon Leffler, Ulf J Nilsson.   

Abstract

Galactose C3-triazole derivatives were synthesized by Cu(I)-catalyzed cycloaddition between acetylenes and galactose C3-azido derivatives. Evaluation against galectin-3, 7, 8N (N-terminal) and 9N (N-terminal) revealed 1,4-disubstituted triazoles to be high-affinity inhibitors of galectin-3 with selectivity over galectin-7, 8N, and 9N. Conformational analysis of 1,4-di- and 1,4,5-tri-substituted galactose C3-triazoles suggested that a triazole C5-substituent interfered sterically with the galectin proteins, which explained their poor affinities compared to the corresponding 1,4-disubstituted triazoles. Introduction of two 1,4-disubstituted triazole moieties onto thiodigalactoside resulted in affinities down to 29 nM for galectin-3. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538469     DOI: 10.1016/j.bmc.2010.05.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  19 in total

Review 1.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

3.  Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.

Authors:  Pingping Li; Shuainan Liu; Min Lu; Gautum Bandyopadhyay; Dayoung Oh; Takeshi Imamura; Andrew M F Johnson; Dorothy Sears; Zhufang Shen; Bing Cui; Lijuan Kong; Shaocong Hou; Xiao Liang; Salvatore Iovino; Steven M Watkins; Wei Ying; Olivia Osborn; Joshua Wollam; Martin Brenner; Jerrold M Olefsky
Journal:  Cell       Date:  2016-11-03       Impact factor: 41.582

4.  Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.

Authors:  Olga V Glinskii; Sudha Sud; Valeri V Mossine; Thomas P Mawhinney; Douglas C Anthony; Gennadi V Glinsky; Kenneth J Pienta; Vladislav V Glinsky
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

Review 5.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

6.  Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3.

Authors:  Carl Diehl; Olof Engström; Tamara Delaine; Maria Håkansson; Samuel Genheden; Kristofer Modig; Hakon Leffler; Ulf Ryde; Ulf J Nilsson; Mikael Akke
Journal:  J Am Chem Soc       Date:  2010-10-20       Impact factor: 15.419

7.  The carbohydrate-binding site in galectin-3 is preorganized to recognize a sugarlike framework of oxygens: ultra-high-resolution structures and water dynamics.

Authors:  Kadhirvel Saraboji; Maria Håkansson; Samuel Genheden; Carl Diehl; Johan Qvist; Ulrich Weininger; Ulf J Nilsson; Hakon Leffler; Ulf Ryde; Mikael Akke; Derek T Logan
Journal:  Biochemistry       Date:  2011-12-07       Impact factor: 3.162

8.  Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering.

Authors:  Olga Blaževitš; Yonatan G Mideksa; Maja Šolman; Alessio Ligabue; Nicholas Ariotti; Hossein Nakhaeizadeh; Eyad K Fansa; Anastassios C Papageorgiou; Alfred Wittinghofer; Mohammad R Ahmadian; Daniel Abankwa
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

9.  Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.

Authors:  Tung-Ju Hsieh; Hsien-Ya Lin; Zhijay Tu; Ting-Chien Lin; Shang-Chuen Wu; Yu-Yao Tseng; Fu-Tong Liu; Shang-Te Danny Hsu; Chun-Hung Lin
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

10.  Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis.

Authors:  Carrie A Duckworth; Scott E Guimond; Paulina Sindrewicz; Ashley J Hughes; Neil S French; Lu-Yun Lian; Edwin A Yates; D Mark Pritchard; Jonathan M Rhodes; Jeremy E Turnbull; Lu-Gang Yu
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.